Telix Pharmaceuticals Limited

As of December 31, 2023, Telix Pharmaceuticals Limited carries a market capitalization of 3.26B, placing it among publicly traded companies globally. Its enterprise value stands at 3.19B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Telix Pharmaceuticals Limited's next confirmed earnings release is scheduled for February 19, 2027.

As of December 31, 2023, Telix Pharmaceuticals Limited has 323.73M shares outstanding.

These figures are as of December 31, 2023.

As of December 31, 2023, Telix Pharmaceuticals Limited maintains a current ratio of 1.42, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2023.

As of the close on October 22, 2026, Telix Pharmaceuticals Limited's stock has declined approximately 18.74% over the past 52 weeks. The 50-day moving average sits at 16.02, while the 200-day moving average is 13.98.

As of December 31, 2023, Telix Pharmaceuticals Limited holds 84.30M in cash and equivalents against 12.26M in total debt, resulting in a net debt position of -77.69M. Total book value stands at 102.65M, with working capital of 47.32M providing operational flexibility.

These figures cover the twelve months ended December 31, 2023. Total shareholder yield is negative at -0.25, meaning Telix Pharmaceuticals Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.